On September 18, 2025, the biopharmaceutical company Innovent Biologics, Inc. announced its operations in San Francisco and Suzhou, China. Innovent, listed as HKEX: 01801, specializes in developing, manufacturing, and distributing top-tier medications for various medical fields including oncology, autoimmune diseases, and cardiovascular conditions.